With a dedication to improving the lives of patients, Synspira is developing a portfolio of rationally designed products, including SNSP113 and SNSP003. These products aim to disrupt mucus accumulation, bacterial bio-film invasion, and address malabsorption syndromes and exocrine pancreatic insufficiency. By advancing these novel therapeutics, Synspira aims to provide better clinical outcomes and reduce the treatment burden for patients with pulmonary diseases. Currently, SNSP113 is undergoing a Phase 2 clinical study for cystic fibrosis. Headquartered in Framingham, MA, Synspira is committed to addressing unmet needs in the field of pulmonary disorders.